The Technical Analyst
Mereo BioPharma Group plc [MREO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Mereo BioPharma Group plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.52% $2.65
America/New_York / 18 apr 2024 @ 13:33
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 370.46 mill |
| EPS: | -0.200 |
| P/E: | -13.22 |
| Earnings Date: | Mar 29, 2024 |
| SharesOutstanding: | 140.06 mill |
| Avg Daily Volume: | 1.635 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -13.22 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.25x |
| Company: PE -13.22 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0000 (-100.00%) $-2.65 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.42 - 2.87 ( +/- 8.51%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-08 | Ekblom Anders | Buy | 45 000 | Share Options (Right to buy) |
| 2024-02-08 | Ekblom Anders | Buy | 19 471 | Deferred Restricted Stock Units |
| 2024-02-08 | Jacquet Pierre | Buy | 45 000 | Share Options (Right to buy) |
| 2024-02-08 | Jacquet Pierre | Buy | 15 553 | Deferred Restricted Stock Units |
| 2024-02-08 | Yoskowitz Marc J | Buy | 45 000 | Share Options (Right to buy) |
| INSIDER POWER |
|---|
| -60.66 |
| Last 97 transactions |
| Buy: 2 158 393 | Sell: 9 188 547 |
Forecast:
15:12 - $2.65
Live Trading Signals (every 1 min)
Forecast
1: 13:42 - $2.64
Forecast 2: 14:32 - $2.65
Forecast 3: 15:12 - $2.65
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.65 (2.52% ) |
| Volume | 0.433 mill |
| Avg. Vol. | 1.635 mill |
| % of Avg. Vol | 26.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MREO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.01 | N/A | Active |
|---|
MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Latest Press Releases
2024-04-03 07:30:00 - Press Release
Mereo Biopharma To Participate In Fireside Chat At The 23rd Annual Needham Virtual Healthcare Conference
London, april 03, 2024 (globe newswire) -- mereo biopharma group plc (nasdaq: mreo) (“mereo” or the “company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that dr. denise scots-knight, chief executive officer, will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024, at 10:15am et / 03:15pm bst.
2024-03-27 16:01:00 - Press Release
Mereo Biopharma Reports Full Year 2023 Financial Results And Provides Corporate Update
Phase 2/3 orbit study and phase 3 cosmic study of setrusumab in osteogenesis imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
2024-03-05 07:30:00 - Press Release
Mereo Biopharma To Participate In Fireside Chat At The Leerink Partners Global Biopharma Conference
London, march 05, 2024 (globe newswire) -- mereo biopharma group plc (nasdaq: mreo) (“mereo” or the “company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that dr. denise scots-knight, chief executive officer, will participate in a fireside chat at the leerink partners global biopharma conference on tuesday, march 12, 2024 at 11:20am et / 03:20pm gmt.
2024-01-08 07:00:00 - Press Release
Mereo Biopharma Provides Update On Pipeline Progress And Corporate Developments
Phase 3 portion of orbit study and phase 3 cosmic study of setrusumab for treatment of osteogenesis imperfecta (oi) conducted by partner ultragenyx expected to complete enrollment around the end of 1q 2024 and 1h 2024, respectively; additional phase 2 data expected in 2024
2023-10-23 16:01:00 - Press Release
Mereo Biopharma Reports On Recent Program Developments And Provides Financial Update
London, oct. 23, 2023 (globe newswire) -- mereo biopharma group plc (nasdaq: mreo) (“mereo” or the “company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
Latest News
2024-04-12 10:36:10 - Zacks Investment Research
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2024-03-14 17:34:14 - Seeking Alpha
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
2023-09-21 07:00:00 - GlobeNewsWire
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.
2023-04-21 13:43:47 - Zacks Investment Research
What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?
Does MEREO BIOPHARMA (MREO) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-03-21 09:01:38 - PennyStocks
4 Hot Penny Stocks To Watch With News This Week
Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-15 11:19:11 - Zacks Investment Research
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-09-22 13:45:08 - Seeking Alpha
Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
This is an update on the previously written report on Mereo BioPharma Group, a London-based clinical-stage biopharma. Frustrated with the lack of engagement from the management, the activist filled a request for a special shareholder meeting aiming to replace 4 incumbent directors.
2022-07-16 11:30:00 - PennyStocks
How to Find Penny Stocks to Buy in Summer 2022
Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-03 11:30:00 - PennyStocks
How to Make a Penny Stocks Watchlist in July 2022
Consider these tips for making a penny stocks watchlist right now The post How to Make a Penny Stocks Watchlist in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-20 11:39:04 - Zacks Investment Research
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.